U.S. retail investor fund flows into Novo Nordisk surged 32-fold on Friday, as the Danish drugmaker's weaker-than-expected ...

European markets were trading higher on Tuesday, in a shortened trading session for Christmas Eve. The pan-European Stoxx 600 ...

The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...

Pfizer's oncology promises are several years from being actualized. Read why investors shouldn't assume that a sustained ...

Novo Nordisk has an opportunity to expand indications on its weight loss drugs. Check out on what could be next for NVO stock ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

The task ahead of Vertex now is to migrate patients already on Trikafta to the new drug. That is supported by data from the ...

The FDA initially rejected the marketing application for Alhemo in 2022, asking for additional data on dosing and monitoring.

Among the many newcomers to the business of weight-loss drugs is Hims & Hers, an American e-pharmacy better known for hawking ...

The coffee chain's stock ticked up from a two-month low clocked Friday when its union announced [a five-day walkout across multiple cities]( ...

Just one hour left in the shortened holiday trading session, so let Brad Smith and Josh Lipton lead you into the Christmas season by covering the biggest market stories heading into the closing bell.